Skip to main content

Advertisement

SpringerLink
Log in

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC.

Methods

This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis.

Results

A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable.

Conclusion

This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  • Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121(5):664–672

    Article  CAS  Google Scholar 

  • Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JH, Kao S, Miller WH Jr et al (2020) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15(4):618–627

    Article  CAS  Google Scholar 

  • Farago AF, Keane FK (2018) Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 7(1):69

    Article  Google Scholar 

  • Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi99–vi105

    Article  Google Scholar 

  • Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737

    Article  CAS  Google Scholar 

  • Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2021) Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22(1):51–65

    Article  CAS  Google Scholar 

  • Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  Google Scholar 

  • Huang L, Shi Y (2020) Prognostic value of pretreatment smoking status for small cell lung cancer: a meta-analysis. Thoracic Cancer 11(11):3252–3259

    Article  CAS  Google Scholar 

  • Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC et al (2021) Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03052-w

    Article  PubMed  PubMed Central  Google Scholar 

  • Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

    Article  CAS  Google Scholar 

  • Pietanza MC, Byers LA, Minna JD, Rudin CM (2015) Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21(10):2244–2255

    Article  CAS  Google Scholar 

  • Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748

    Article  CAS  Google Scholar 

  • Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T et al (2020) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 38(21):2369

    Article  CAS  Google Scholar 

  • Sahin AB, Cubukcu E, Ocak B, Deligonul A, Kacan T, Orhan SO et al (2020) Chemo-immunotherapy with atezolizumab in extensive-stage small-cell lung cancer; Single-Center Experience. Int J Hematol Oncol. https://doi.org/10.4999/uhod.204252

    Article  Google Scholar 

  • Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV et al (2020) Association of sex, age, and Eastern Cooperative Oncology Group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open 3(8):e2012534

    Article  Google Scholar 

Download references

Acknowledgements

We thank Dr. Murat Ayhan, Dr. Eyyüp Çavdar, Dr. Turgut Kaçan, Dr. Çiğdem Usul Avşar, and Dr. Ahmet Şiyar Ekinci for their contributions to the study.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey

    Mustafa Gürbüz, Elif Berna Köksoy, Sevinç Ballı & Ahmet Demirkazık

  2. Department of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul, Turkey

    Yasin Kutlu, Ahmet Bilici & Ömer Fatih Ölmez

  3. Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey

    Erman Akkuş

  4. Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey

    Naziyet Köse

  5. Department of Medical Oncology, Faculty of Medicine, Bahçeşehir University, Göztepe Medical Park Hospital, Istanbul, Turkey

    Bala Başak Öven

  6. Department of Medical Oncology, Acıbadem Altunizade Hospital, Istanbul, Turkey

    Başak Oyan Uluç

  7. Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey

    Atike Gökçen Demiray

  8. Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey

    Dilek Erdem & Yasemin Kemal

  9. Department of Medical Oncology, Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkey

    Bilgin Demir

  10. Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey

    Nazım Serdar Turhal & Necdet Üskent

  11. Department of Medical Oncology, Koç University Hospital, Istanbul, Turkey

    Sinem Akbaş, Fatih Selçukbiricik & Perran Fulden Yumuk

  12. Department of Medical Oncology, Mersin City Hospital, Mersin, Turkey

    Ali İnal

  13. Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey

    Devrim Çabuk

  14. Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey

    Çağlar Ünal

  15. Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey

    Mutlu Hızal & Mehmet Ali Nahit Şendur

  16. Meram Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey

    Mustafa Korkmaz

  17. Department of Medical Oncology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey

    Nuri Karadurmuş & İsmail Ertürk

  18. Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey

    Sema Sezgin Göksu & Ali Murat Tatlı

  19. Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Deniz Can Güven

  20. Department of Medical Oncology, Faculty of Medicine, İstinye University, Liv Ankara Hospital, Ankara, Turkey

    Saadettin Kılıçkap

  21. Department of Medical Oncology, Faculty of Medicine, İstanbul University, Istanbul, Turkey

    Nail Paksoy & Adnan Aydıner

  22. Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey

    Havva Yeşil Çınkır

  23. Department of Medical Oncology, Bağcılar Training and Research Hospital, Istanbul, Turkey

    Özlem Özkul

  24. Department of Medical Oncology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

    Akın Öztürk

  25. Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey

    Atike Pınar Erdoğan

  26. Department of Medical Oncology, Maslak Acıbadem Hospital, Istanbul, Turkey

    Özlem Er

Authors
  1. Mustafa Gürbüz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasin Kutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erman Akkuş
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elif Berna Köksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naziyet Köse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bala Başak Öven
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Başak Oyan Uluç
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atike Gökçen Demiray
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dilek Erdem
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bilgin Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nazım Serdar Turhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Necdet Üskent
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sinem Akbaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Fatih Selçukbiricik
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ali İnal
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ahmet Bilici
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ömer Fatih Ölmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Devrim Çabuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Çağlar Ünal
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mutlu Hızal
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Mehmet Ali Nahit Şendur
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mustafa Korkmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Nuri Karadurmuş
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. İsmail Ertürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Sema Sezgin Göksu
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Ali Murat Tatlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Deniz Can Güven
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Saadettin Kılıçkap
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Nail Paksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Adnan Aydıner
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Havva Yeşil Çınkır
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Özlem Özkul
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Akın Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Sevinç Ballı
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Yasemin Kemal
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Atike Pınar Erdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Özlem Er
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Perran Fulden Yumuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. Ahmet Demirkazık
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Idea and design: MG, EA, EBK, AD. Data collection: MG, YK, EA, EBK, NK, BBÖ, BOU, AGD, DE, BD, NST, NÜ, SA, FS, Aİ, AB, ÖFÖ, DÇ, ÇÜ, MH, MANŞ, MK, NK, İE, SSG, AMT, DCG, SK, NP, AA, HYÇ, ÖÖ, AÖ, YK, APE, ÖE, PFY, AD. Statistical analysis and writing: MG, EA, EBK, AD. Revision of the article for important intellectual content: EBK, MANŞ, AMT, SK, PFY, AD.

Corresponding author

Correspondence to Mustafa Gürbüz.

Ethics declarations

Conflict of interest

The authors declare no competing financial interests.

Ethics approval, consent to participate, consent for publication

Approval of ethical committee was obtained from the Ankara University Faculty of Medicine Ethics Committee in compliance with the Helsinki Declaration (Decision number: İ9-597-20).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gürbüz, M., Kutlu, Y., Akkuş, E. et al. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. J Cancer Res Clin Oncol 148, 3547–3555 (2022). https://doi.org/10.1007/s00432-022-04087-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-022-04087-x

Keywords

Search

Navigation